Elicio Announces Additional Immunogenicity Data From Ongoing Phase 2 AMPLIFY-7P Trial Evaluating ELI-002 7P In Patients With mKRAS PDAC And New Preclinical Data On Immunotherapy Candidate ELI-004, For Treatment Of Solid Tumors

• SITC abstracts highlight updated immunogenicity results from the Phase 2 AMPLIFY-7P trial of ELI-002 7P and preclinical data on the use of intratumoral ELI-004 (AMP-CpG) for solid tumor immunotherapy
• ELI-002 7P induced mKRAS-specific T cell responses in 99% of evaluable patients (89/90), demonstrating potent and consistent immune activation
• Robust immune responses were elicited across all seven mKRAS antigens, with >80% response rate to each individual KRAS mutation and 88% of patients generating responses to their own tumor-specific mutation
• 86.8% (66/76) of patients induced cytotoxic mKRAS-specific T cell responses; 75% (57/76) induced CD8+ T cells and 75% (57/76) induced CD4+ T cells
• mKRAS-specific T cell responses were observed across diverse HLA types, supporting the potential applicability of ELI-002 7P across a broad and genetically diverse patient population
   

BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company"))), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced additional immunogenicity data from the ongoing Phase 2 AMPLIFY-7P trial evaluating ELI-002 7P in patients with mKRAS pancreatic ductal adenocarcinoma ("PDAC") and new preclinical data on immunotherapy candidate ELI-004, for treatment of solid tumors.

The data will be presented at the Society for Immunotherapy of Cancer ("SITC") 2025 Annual Meeting (Nov. 7-8, 2025, in National Harbor, MD).